Jianjun Zhang1, Kathryn A Gold, Heather Y Lin, Stephen G Swisher, Yan Xing, J Jack Lee, Edward S Kim, William N William. 1. *Department of Thoracic/Head & Neck Medical Oncology, †Department of Genomic Medicine, ‡Department of Biostatistics, §Department of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, The University of Texas, Houston TX; ‖Department of Medicine, Harvard Medical School, Mount Auburn Hospital, Cambridge, MA; and ¶Levine Cancer Institute, Carolina HealthCare System, Charlotte, NC.
Abstract
INTRODUCTION: Tumor size is a known prognostic factor for early stage non-small-cell lung cancer (NSCLC), but its significance in node-positive and locally invasive NSCLC has not been extensively characterized. We queried the Surveillance, Epidemiology, and End Results database to evaluate the prognostic value of tumor size for early stage and node-positive and locally invasive NSCLC. METHODS: Patients in Surveillance, Epidemiology, and End Results registry with NSCLC diagnosed between 1998 and 2003 were analyzed. Tumor size was analyzed as a continuous variable. Other demographic variables included age, gender, race, histology, primary tumor extension, node status, and primary treatment modality (surgery vs. radiation). The Kaplan-Meier method was used to estimate overall survival (OS). Cox proportional hazard model was used to evaluate whether tumor size was an independent prognostic factor. RESULTS: In all, 52,287 eligible patients were subgrouped based on tumor extension and node status. Tumor size had a significant effect on OS in all subgroups defined by tumor extension or node status. In addition, tumor size also had statistically significant effect on OS in 15 of 16 subgroups defined by tumor extension and nodal status after adjustment for other clinical variables. Our model incorporating tumor size had significantly better predictive accuracy than our alternative model without tumor size. CONCLUSIONS: Tumor size is an independent prognostic factor, for early stage and node-positive and locally invasive disease. Prediction tools, such as nomograms, incorporating more detailed information not captured in detail by the routine tumor, node, metastasis classification, may improve prediction accuracy of OS in NSCLC.
INTRODUCTION:Tumor size is a known prognostic factor for early stage non-small-cell lung cancer (NSCLC), but its significance in node-positive and locally invasive NSCLC has not been extensively characterized. We queried the Surveillance, Epidemiology, and End Results database to evaluate the prognostic value of tumor size for early stage and node-positive and locally invasive NSCLC. METHODS:Patients in Surveillance, Epidemiology, and End Results registry with NSCLC diagnosed between 1998 and 2003 were analyzed. Tumor size was analyzed as a continuous variable. Other demographic variables included age, gender, race, histology, primary tumor extension, node status, and primary treatment modality (surgery vs. radiation). The Kaplan-Meier method was used to estimate overall survival (OS). Cox proportional hazard model was used to evaluate whether tumor size was an independent prognostic factor. RESULTS: In all, 52,287 eligible patients were subgrouped based on tumor extension and node status. Tumor size had a significant effect on OS in all subgroups defined by tumor extension or node status. In addition, tumor size also had statistically significant effect on OS in 15 of 16 subgroups defined by tumor extension and nodal status after adjustment for other clinical variables. Our model incorporating tumor size had significantly better predictive accuracy than our alternative model without tumor size. CONCLUSIONS:Tumor size is an independent prognostic factor, for early stage and node-positive and locally invasive disease. Prediction tools, such as nomograms, incorporating more detailed information not captured in detail by the routine tumor, node, metastasis classification, may improve prediction accuracy of OS in NSCLC.
Authors: Paul C Lee; Robert J Korst; Jeffrey L Port; Yaniv Kerem; Amanda L Kansler; Nasser K Altorki Journal: J Thorac Cardiovasc Surg Date: 2006-10-30 Impact factor: 5.209
Authors: Andrea Campione; Tommaso Ligabue; Luca Luzzi; Claudia Ghiribelli; Piero Paladini; Luca Voltolini; Maurizio Di Bisceglie; Mario Lonzi; Giuseppe Gotti Journal: Asian Cardiovasc Thorac Ann Date: 2004-06
Authors: Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal Journal: Science Date: 2014-10-10 Impact factor: 47.728
Authors: S Yuan; Z Yu; Q Liu; M Zhang; Y Xiang; N Wu; L Wu; Z Hu; B Xu; T Cai; X Ma; Y Zhang; C Liao; L Wang; P Yang; L Bai; Y Li Journal: Oncogene Date: 2016-05-09 Impact factor: 9.867
Authors: Pei N Ding; Tara L Roberts; Wei Chua; Therese M Becker; Nicole Caixeiro; Paul de Souza; Bo Gao; Chee K Lee; Malinda Itchins; Helen Westman; Stephen Clarke; Prunella Blinman; Steven Kao; Tom John; Jose L Leal; Victoria J Bray Journal: Transl Lung Cancer Res Date: 2021-04
Authors: Holger Moch; Alwin Krämer; Chantal Pauli; Tilmann Bochtler; Linda Mileshkin; Giulia Baciarello; Ferran Losa; Jeffrey S Ross; George Pentheroudakis; George Zarkavelis; Suayib Yalcin; Mustafa Özgüroğlu; Andreas Beringer; Jeremy Scarato; Mathis Mueller-Ohldach; Marlene Thomas Journal: Oncologist Date: 2021-03-25